Cardurion Pharmaceuticals
Latest round
- Series B
Last raised
- Jul 2024
Total raised
- $260M
Investors
- 11
About Cardurion Pharmaceuticals
Cardurion Pharmaceuticals, Inc.Founded in 2017, Cardurion Pharmaceuticals specializes in developing drug candidates for cardiovascular diseases.Cardurion Pharmaceuticals focuses on innovative therapeutics for cardiovascular diseases, primarily through the development of drug candidates targeting PDE9 and CaMKII signaling pathways. Their lead products include a PDE9 inhibitor aimed at treating both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), presenting a potential foundational treatment option when integrated with existing medical therapies. Additionally, Cardurion is pioneering a CaMKII inhibitor, which is the first of its kind to be evaluated in clinical studies, positioning the company to address multiple cardiovascular conditions, including rare genetic diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT).The revenue model for Cardurion Pharmaceuticals is based on strategic partnerships and collaborations within the pharmaceutical industry, as well as clinical trial agreements with healthcare entities. Transactions typically occur through B2B relationships where Cardurion partners with other pharmaceutical companies or biotech firms to co-develop products, sharing in the costs and potential revenue streams derived from successful drug commercialization.Cardurion Pharmaceuticals aims to expand its product pipeline with upcoming innovative therapeutics targeting significant cardiovascular conditions.411 mn to enhance its research capabilities and expedite clinical trials for its leading drug candidates. The company also intends to explore market expansion opportunities in Europe and Asia by 2025, enhancing its global reach within the pharmaceutical sector. Recently, Takeda Pharmaceutical made an investment in Cardurion, indicating potential collaborative opportunities that could further support the company’s growth initiatives.
Who invested in Cardurion Pharmaceuticals
11 investors across 1 round
See all investors in Cardurion Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Jul 16, 2024
Amount
$260M
Investors
Questions about Cardurion Pharmaceuticals
Who invested in Cardurion Pharmaceuticals?
Cardurion Pharmaceuticals has 11 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cardurion Pharmaceuticals raised?
Cardurion Pharmaceuticals has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Cardurion Pharmaceuticals last raise money?
Cardurion Pharmaceuticals's most recent round on record is a Series B, in Jul 2024.
What does Cardurion Pharmaceuticals do?
Cardurion Pharmaceuticals, Inc.
Where is Cardurion Pharmaceuticals headquartered?
Cardurion Pharmaceuticals is headquartered in Burlington, US.
Which VCs invest in companies like Cardurion Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Cardurion Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Cardurion Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.